Responding to 'C. diff' -- concerted action needed to control health care-related infection

November 16, 2015

November 16, 2015 - Appropriate use of antibiotics is a critical step toward controlling the ongoing epidemic of health care-related Clostridium difficile infection (CDI), according to a special article in the November issue of Infectious Diseases in Clinical Practice. The journal, affiliated with the National Foundation for Infectious Diseases (NFID), the journal is published by Wolters Kluwer.

The NFID Clinical Update emphasizes the urgent need for prevention steps to reduce the growing burden of C-diff infection in the population. Summarizing a recent NFID webinar by Drs. Carolyn V. Gould and L. Clifford McDonald of the Centers for Disease Control and Prevention (CDC), the article was authored by the presenters along with Dr. Thomas M. File, Jr., Editor-in-Chief of Infectious Diseases in Clinical Practice.

'Antibiotic Stewardship' Is Key to Fighting C. difficile Infection

Sometimes called "C-diff," Clostridium difficile is a type of bacteria that can cause serious, potentially life-threatening cause of diarrhea. Spores of Clostridium difficile can persist on any surface, device, or material, allowing the infection to spread easily. In 2011, the total number of CDI cases in the United States was estimated at over 450,000. The same study reported 29,000 deaths within 30 days after CDI diagnosis, at least half of which were likely attributable to C-diff.

Although Clostridium difficile is a significant hospital-acquired infection, three-fourths of CDI cases are now diagnosed outside of hospitals. However, studies suggest that more than 80 percent of patients with "community-associated" C-diff have a recent healthcare exposure, such as visits to a doctor or dentist.

Previous antibiotic treatment is the most important risk factor for CDI. Antibiotics can disrupt the normal balance of bacteria in the intestines, providing an environment where C. difficile spores can multiply and produce diarrhea-causing toxins. The incidence of CDI rose dramatically in the past decade, likely related to the emergence of a variant C-diff strain (NAP1/207) that is more virulent and more resistant to antibiotics.

Appropriate use of antibiotics--or "antibiotic stewardship"--is considered essential for meaningful reduction in CDI rates. Recent studies have identified key elements for successful hospital antibiotic stewardship programs, including avoiding unnecessary antibiotic treatment and choosing antibiotics with a lower risk of CDI, when possible. In the United Kingdom, a national antibiotic stewardship program reduced hospital CDI rates by more than 60 percent.

The CDC has identified six key components of efforts to prevent CDI: Drs. Gould, McDonald, and File hope their clinical update will increase awareness of the C-diff epidemic and measures to limit its impact. They conclude, "The current epidemiology of CDI necessitates active participation from all segments of the healthcare community in a comprehensive approach to reduce the burden of CDI through effective antibiotic stewardship and active measures to reduce spore transmission."
-end-
Further information--including steps patients and communities can take to help stop C-diff--is available online via the CDC's "Vital Signs" program. The webinar by Drs. Gould and MacDonald can be viewed online via the NFID website. Healthcare professionals can earn continuing medical education credits from either Infectious Diseases in Clinical Practice or the NFID.

Click here to read "Causes, Burden, and Prevention of Clostridium difficile Infection."

Article: "Causes, Burden, and Prevention of Clostridium difficile Infection" (doi: 10.1097/IPC.0000000000000331)

About Infectious Diseases in Clinical Practice

Medical professionals seeking an infectious diseases journal with true clinical value need look no further than Infectious Diseases in Clinical Practice. Here, clinicians can get full coverage consolidated into one resource, with pertinent new developments presented in a way that makes them easy to apply to patient care. From HIV care delivery to Hepatitis C virus testing...travel and tropical medicine...and infection surveillance, prevention, and control, Infectious Diseases in Clinical Practice delivers the vital information needed to optimally prevent and treat infectious diseases.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit http://www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Wolters Kluwer Health

Related Antibiotics Articles from Brightsurf:

Insights in the search for new antibiotics
A collaborative research team from the University of Oklahoma, the Memorial Sloan Kettering Cancer Center and Merck & Co. published an opinion article in the journal, Nature Chemical Biology, that addresses the gap in the discovery of new antibiotics.

New tricks for old antibiotics
The study published in the journal Immunity reveals that tetracyclines (broad spectre antibiotics), by partially inhibiting cell mitochondria activity, induce a compensatory response on the organism that decreases tissue damage caused during infection.

Benefits, risks seen with antibiotics-first for appendicitis
Antibiotics are a good choice for some patients with appendicitis but not all, according to study results published today in the New England Journal of Medicine.

How antibiotics interact
Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics / study in 'Nature Communications'

Are antivitamins the new antibiotics?
Antibiotics are among the most important discoveries of modern medicine and have saved millions of lives since the discovery of penicillin almost 100 years ago.

Hygiene reduces the need for antibiotics by up to 30%
A new paper published in the American Journal of Infection Control (AJIC), finds improved everyday hygiene practices, such as hand-washing, reduces the risk of common infections by up to 50%, reducing the need for antibiotics, by up to 30%.

Antibiotics: City dwellers and children take the most
City dwellers take more antibiotics than people in rural areas; children and the elderly use them more often than middle-aged people; the use of antibiotics decreases as education increases, but only in rich countries: These are three of the more striking trends identified by researchers of the NRW Forschungskolleg ''One Health and Urban Transformation'' at the University of Bonn.

Metals could be the link to new antibiotics
Compounds containing metals could hold the key to the next generation of antibiotics to combat the growing threat of global antibiotic resistance.

Antibiotics from the sea
The team led by Prof. Christian Jogler of Friedrich Schiller University, Jena, has succeeded in cultivating several dozen marine bacteria in the laboratory -- bacteria that had previously been paid little attention.

Antibiotics not necessary for most toothaches, according to new ADA guideline
The American Dental Association (ADA) announced today a new guideline indicating that in most cases, antibiotics are not recommended for toothaches.

Read More: Antibiotics News and Antibiotics Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.